Major role for hypoxia inducible factor-1 and the endothelin system in promoting myocardial infarction and hypertension in an animal model of obstructive sleep apnea.
OBJECTIVE
Our aim was to investigate the involvement of the endothelin (ET) system in the cardiovascular consequences of intermittent hypoxia (IH).


BACKGROUND
Obstructive sleep apnea (OSA) syndrome is an important risk factor for cardiovascular morbidity. Chronic IH, a major component of OSA, is thought to be responsible for most of the cardiovascular complications occurring during OSA, but the underlying mechanisms remain to be determined.


METHODS
Chronic IH was applied in rats genetically prone to develop hypertension (spontaneous hypertensive rats [SHR]) and their normotensive controls. The cardiovascular effects were assessed in vivo and in Langendorff perfused hearts. Hypoxia inducible factor (HIF)-1 activity and targeting of the myocardial ET-1 gene and activation of the ET system were investigated using tissue chromatin immunoprecipitation, enzyme-linked immunoadsorbent assay, immunostaining, and Western blotting.


RESULTS
Chronic IH enhanced hypertension development and infarct size in SHR compared with that seen in control rats. This was accompanied by an increase in myocardial big ET-1, ET-1, and ET-A receptor expression and by an enhanced coronary vascular reactivity to ET-1 in SHR only. Myocardial HIF-1 activity was increased, and HIF-1 was shown to be linked to the promoter of the myocardial ET-1 gene after chronic IH only. Moreover, administration of bosentan, a mixed ET receptor antagonist, during chronic IH prevented both the increase in blood pressure and in infarct size.


CONCLUSIONS
In SHR, activation of the ET system, mediated by HIF-1 activity, is responsible for the enhanced susceptibility to chronic IH and for its associated cardiovascular consequences leading to hypertension and ischemic injury. Furthermore, the beneficial effects of bosentan suggest exploring ET antagonists as possible therapeutic tools in OSA.
INSERM, Grenoble, France.
Elise
E
Belaidi
Marie
M
Joyeux-Faure
Christophe
C
Ribuot
Sandrine H
SH
Launois
Patrick
P
Levy
Diane
D
Godin-Ribuot
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D000077300:Bosentan; D004195:Disease Models, Animal; D019332:Endothelin-1 / Q000235:genetics* / Q000378:metabolism; D020022:Genetic Predisposition to Disease; D006321:Heart / Q000187:drug effects; D006973:Hypertension / Q000209:etiology / Q000235:genetics* / Q000378:metabolism; D000860:Hypoxia / Q000209:etiology; D051793:Hypoxia-Inducible Factor 1 / Q000235:genetics* / Q000378:metabolism; D008297:Male; D009203:Myocardial Infarction / Q000209:etiology / Q000235:genetics* / Q000378:metabolism; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D020181:Sleep Apnea, Obstructive / Q000150:complications*; D013449:Sulfonamides / Q000494:pharmacology
D000959:Antihypertensive Agents; D019332:Endothelin-1; D051793:Hypoxia-Inducible Factor 1; D013449:Sulfonamides; D000077300:Bosentan